Customer Center
Login | Register

Investor Relations

  • Banner Image

News Releases

Date Title  
Toggle Summary Luminex Corporation To Release Fourth Quarter and Full-Year 2019 Results After Market Close On February 10, 2020
AUSTIN, Texas , Jan. 23, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the fourth quarter and full-year ended December 31, 2019 on Monday, February 10, 2020 after the market close. The company will host a conference call that day at 5:00
Toggle Summary Luminex Corporation Announces 2019 Highlights and 2020 Guidance; Company to Present at 38th Annual J.P. Morgan Healthcare Conference
AUSTIN, Texas , Jan. 12, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2019 highlights and 2020 guidance. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP").   Preliminary results, contained herein, are based on
Toggle Summary Luminex Corporation Declares Fourth Quarter Cash Dividend
AUSTIN, Texas , Dec. 6, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the fourth quarter of 2019 of $0.09 per share of common stock payable on January 15 , 2019 to stockholders of record as of the
Toggle Summary Luminex Corporation to Present at the Piper Jaffray 31st Annual Healthcare Conference on December 4, 2019
AUSTIN, Texas , Nov. 25, 2019 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that Harriss Currie , Senior Vice President of Finance and CFO, will participate in investor meetings and present at the Piper Jaffray 31 st Annual Healthcare Conference on Wednesday, December 4, 2019
Toggle Summary Luminex Corporation Reports Third Quarter 2019 Results and Submission of VERIGENE II Gastrointestinal Flex Assay to the FDA
AUSTIN, Texas , Nov. 4, 2019 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its third quarter ended September 30, 2019 . All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP").
Toggle Summary Luminex Corporation To Release Third Quarter 2019 Results After Market Close On November 4, 2019
AUSTIN, Texas , Oct. 25, 2019 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the third quarter ended September 30, 2019 on Monday, November 4, 2019 after the market close.  The company will host a conference call that day at 5:00 p.m.
Toggle Summary Luminex Receives FDA 510(k) Clearance for the ARIES® MRSA Assay
  AUSTIN, Texas , Oct. 1, 2019 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) announced that the company has received U.S. Food and Drug Administration ( FDA ) 510(k) clearance for the ARIES ® MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative,
Toggle Summary Luminex Corporation to Present at the Cantor Global Healthcare Conference on October 2, 2019
  AUSTIN, Texas , Sept. 26, 2019 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir , President and Chief Executive Officer, and Harriss Currie , Senior Vice President of Finance and CFO, will participate in investor meetings and present at the Cantor Global
Toggle Summary Luminex Corporation to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
AUSTIN, Texas , Sept. 3, 2019 /PRNewswire/ --  Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir , President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference to be held September 9-11, 2019
Toggle Summary Luminex Corporation Reports Second Quarter 2019 Financial Results And Increase In Quarterly Dividend
AUSTIN, Texas , July 31, 2019 /PRNewswire/ --  Luminex Corporation (Nasdaq: LMNX) today announced financial results for the second quarter 2019. Financial and operating highlights for the quarter include: Second quarter consolidated revenue increased 4% to $83.1 million from $79.6 million in the